Table 1.
Characteristics of the patients involved in the study
| Characteristics | Study group (lymphoid malignancies, n = 221) | Control group 1 (orthopedics, n = 442) | Control group 2 (ENT, n = 437) | Combined control group † (n = 879) |
|---|---|---|---|---|
| Male : female ratio | 86:136 | 172:272 | 168:272 | 340:544 |
| Age range, median (years) | 46–94, 64 | 44–95, 63 | 44–91, 61 | 44–91, 61 |
| No. patients by age group | ||||
| 40–49 years | 23 (10.4%) | 39 (8.8%) | 45 (10.4%) | 84 (9.6%) |
| 50–59 years | 64 (29.0%) | 143 (32.4%) | 156 (35.7%) | 299 (34.0%) |
| 60–69 years | 66 (29.9%) | 120 (27.2%) | 117 (26.8%) | 237 (27.0%) |
| 70–95 years | 68 (30.8%) | 140 (31.7%) | 119 (27.2%) | 259 (29.5%) |
| Serum levels of total cholesterol (mg/dL) (mean ± SD) | 171.3 ± 43.9 | 189.0 ± 35.8 | 189.9 ± 35.1 | 189.5 ± 35.4 |
| No. patients with hypercholesterolemia ‡ | 21 (9.5%) | 78 (17.6%) | 84 (19.2%) | 162 (18.4%) |
| History of statin use | ||||
| Yes | 29 (13.3%) | 33 (7.5%) | 31 (7.1%) | 64 (7.3%) |
| Pravastatin | 25 (86.2%) | 24 (72.7%) | 17 (54.8%) | 41 (64.1%) |
| Simvastatin | 4 (13.8%) | 9 (27.3%) | 13 (41.9%) | 22 (34.4%) |
| Fluvastatin | 0 (0%) | 0 (0%) | 1 (3.2%) | 1 (1.6%) |
| No | 189 (86.7%) | 409 (92.5%) | 406 (92.9%) | 815 (92.7%) |
| Unknown | 3 (1.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| No. patients receiving statins/no. patients with hypercholesterolemia ‡ | 3/21 (14.2%) | 11/78 (14.1%) | 10/84 (11.9%) | 21/162 (13.0%) |
| Anti‐HBsAg (positive/negative/unknown) | 7/207/7 | 5/429/8 | 10/426/6 | 15/855/14 |
| Anti‐HCVAb (positive/negative/unknown) | 22/193/6 | 25/410/7 | 16/418/8 | 41/828/15 |
| Histological Subtypes and Phenotypes of Lymphoid Malignancies | ||||
| B cell neoplasms | 192 (86.9) | |||
| Diffuse large, B | 67 (30.3) | |||
| Plasma cell myeloma | 59 (26.7) | |||
| Follicular | 29 (13.1) | |||
| Mantle cell | 8 (4.2) | |||
| Others | 37 (19.3) | |||
| T‐cell/NK‐cell Neoplasms | 20 (9.0) | |||
| Peripheral, T | 7 (3.2) | |||
| Angioimmunoblastic, T | 6 (2.7) | |||
| Others | 7 (3.2) | |||
| Hodgkin lymphoma | 7 (3.2) | |||
| Classical | 6 (2.7) | |||
| Nodular lymphocyte | 1 (0.5) | |||
| NHL, unclassifiable | 2 (0.9) | |||
†
Two control groups were combined.
‡
Patients whose blood cholesterol levels were 200 mg/dL or higher were defined as having hypercholesterolemia. ENT, otorhinolaryngology; HBsAg, Hepatitis B surface antigens; HCVAb, Hepatitis C virus antibodies.